ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 117 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $400,867 | -74.7% | 75,493 | -54.5% | 0.00% | – |
| Q2 2023 | $1,582,752 | +7.6% | 166,081 | +24.2% | 0.00% | – |
| Q1 2023 | $1,471,294 | -49.1% | 133,754 | -31.5% | 0.00% | -100.0% |
| Q4 2022 | $2,890,470 | +25.7% | 195,302 | +62.2% | 0.00% | – |
| Q3 2022 | $2,300,000 | +75.0% | 120,395 | +95.2% | 0.00% | – |
| Q2 2022 | $1,314,000 | +77.6% | 61,681 | +60.5% | 0.00% | – |
| Q1 2022 | $740,000 | -65.1% | 38,432 | -62.4% | 0.00% | – |
| Q4 2021 | $2,122,000 | +106.4% | 102,334 | +137.8% | 0.00% | – |
| Q3 2021 | $1,028,000 | -69.4% | 43,035 | -65.0% | 0.00% | – |
| Q2 2021 | $3,356,000 | +151.6% | 122,990 | +166.8% | 0.00% | – |
| Q1 2021 | $1,334,000 | +112.4% | 46,102 | +106.3% | 0.00% | – |
| Q4 2020 | $628,000 | -36.6% | 22,348 | -33.9% | 0.00% | – |
| Q3 2020 | $990,000 | +182.1% | 33,797 | +191.6% | 0.00% | – |
| Q2 2020 | $351,000 | – | 11,592 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
| Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
| 1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
| Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
| MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
| Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
| SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
| Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |